Japan Lifeline Co., Ltd.

Tokyo Stock Exchange 7575.T

Japan Lifeline Co., Ltd. Price to Sales Ratio (P/S) on February 06, 2025: 2.16

Japan Lifeline Co., Ltd. Price to Sales Ratio (P/S) is 2.16 on February 06, 2025, a 29.29% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Japan Lifeline Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 2.16 on February 05, 2025, which is 0.10% above the current Price to Sales Ratio (P/S).
Japan Lifeline Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 1.45 on August 05, 2024, which is -32.56% below the current Price to Sales Ratio (P/S).
Japan Lifeline Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 1.69.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 7575.T

Japan Lifeline Co., Ltd.

CEO	Mr. Keisuke Suzuki
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	Tennoz Ocean Square
Employees	1,216
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Hardware & Electronics

Description

Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts; and transvascular intervention products include PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and atrial septal defect closure devices. The company offers gastrointestinal intervention products that consist of radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years